BioLineRx reports $0.4 million in third quarter 2025 revenues
BioLineRX Ltd. reported $0.4 million in revenues for Q3 2025, primarily from royalties related to APHEXDA's commercialization in the U.S. This is a decrease from Q3 2024, which included significant upfront payments and sales. The company also reported a net financial income of $0.1 million, a shift from a $1.2 million expense in 2024, due to loan paydowns. Additionally, BioLineRX formed a joint venture with Hemispherian AS to advance GLIX1, with clinical trials expected in early 2026.
BioLineRX Ltd. reported total revenues of $0.4 million for the third quarter of 2025, reflecting royalties from Ayrmid related to the commercialization of APHEXDA in stem cell mobilization in the U.S. This compares to revenues in the third quarter of 2024, which included a $3.2 million upfront payment from Gloria Biosciences and $1.7 million from direct commercial sales prior to the Ayrmid transaction in November 2024. Net financial income for the third quarter of 2025 was $0.1 million, compared to net financial expenses of $1.2 million in the same period of 2024. The reduction in financial expenses is attributed to a significant paydown of the BlackRock loan balance after the Ayrmid transaction. During the quarter, BioLineRX established a joint venture with Hemispherian AS to advance GLIX1, a DNA damage response-targeting molecule, with a Phase 1/2a clinical trial expected to begin in the first quarter of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLineRX Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-003941), on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
